Unity Biotechnology, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
CEO Anirvan Ghosh sold shares of Unity Biotechnology to cover tax withholding obligations related to vesting Restricted Stock Units.
Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, sold 17,852 shares of common stock to cover tax withholding obligations.
Lynne Sullivan, CFO of Unity Biotechnology, sold 21,867 shares of common stock on April 2, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.
Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, reports the sale and acquisition of company stock and stock options.
Lynne Marie Sullivan, CFO of Unity Biotechnology, reports the acquisition of 65,000 shares of common stock and options to purchase 106,000 shares following the satisfaction of performance criteria.
Anirvan Ghosh, CEO of Unity Biotechnology, reports the acquisition of restricted stock units and stock options following the satisfaction of performance criteria.
Director Yehia Hashad acquired 20,000 stock options in Unity Biotechnology, Inc. on March 8, 2025, according to a Form 4 filing.
Lynne Marie Sullivan, CFO of Unity Biotechnology, sold 153 shares of common stock on February 4, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.
Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, sold 164 shares of common stock to cover tax withholding obligations.
Anirvan Ghosh, CEO of Unity Biotechnology, sold 642 shares of common stock on February 4, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.
Alexander Hieu Nguyen, CLO and Head of Operations at Unity Biotechnology, acquired 150,000 stock options on January 22, 2025.
Lynne Marie Sullivan, CFO of Unity Biotechnology, was granted stock options for 150,000 shares on January 22, 2025.
Anirvan Ghosh, CEO of Unity Biotechnology, was granted stock options for 450,000 shares on January 22, 2025.
Federico Grossi, Chief Medical Officer of Unity Biotechnology, acquired 150,000 stock options on January 6, 2025, according to a Form 4 filing.
Anirvan Ghosh, CEO of Unity Biotechnology, sold 432 shares of common stock at $1.29 per share on November 4, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Lynne Marie Sullivan, CFO of Unity Biotechnology, sold 136 shares of common stock on November 4, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Alexander Hieu Nguyen, Chief Legal Officer of Unity Biotechnology, sold 149 shares of common stock on November 4, 2024, to cover tax withholding obligations.
Alexander Hieu Nguyen, Chief Legal Officer of Unity Biotechnology, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.
Anirvan Ghosh, CEO of Unity Biotechnology, sold 604 shares of common stock on August 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Lynne Marie Sullivan, CFO of Unity Biotechnology, sold shares of common stock on August 2, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Alexander Hieu Nguyen, Chief Legal Officer of Unity Biotechnology, sold 78 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.
Anirvan Ghosh, CEO of Unity Biotechnology, sold 1,214 shares of common stock on June 25, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Lynne Marie Sullivan, CFO of Unity Biotechnology, sold 324 shares of common stock on June 25, 2024, to cover tax withholding obligations related to vesting Restricted Stock Units.
Camille D. Samuels, a director of Unity Biotechnology, acquired stock options for 10,000 shares of common stock on June 21, 2024.
Margo R. Roberts, a director of Unity Biotechnology, acquired 10,000 stock options on June 21, 2024, according to a recent SEC filing.
Paul L. Berns, a director at Unity Biotechnology, acquired stock options for 10,000 shares on June 21, 2024.
Nathaniel E. David, a director at Unity Biotechnology, acquired stock options for 10,000 shares of common stock on June 21, 2024.
Keith R. Leonard, a director at Unity Biotechnology, acquired 10,000 stock options on June 21, 2024, exercisable for common stock.
Gilmore Neil O'Neill, a director at Unity Biotechnology, acquired stock options for 10,000 shares of common stock on June 21, 2024.
Michael P. Samar, a director at Unity Biotechnology, acquired stock options for 10,000 shares on June 21, 2024.